Accuray Incorporated announced the signing of a multi-year master research and collaboration agreement with the University of Heidelberg. Accuray and the University of Heidelberg will collaborate on cutting-edge research in radiation oncology to advance treatment technology and provide health care professionals with the most advanced tools for treating patients. Long standing research collaboration with the University of Heidelberg has been in existence surrounding TomoTherapy technology, which included exploration of new treatment options with helical TomoTherapy and associated journal publications about advanced use of this expanded application. The University of Heidelberg was the first TomoTherapy installation in Germany in 2006. A second TomoTherapy System was installed in 2010. Together these systems -a TomoHD and a TomoTherapy Hi-Art -- treat approximately 700 patients per year, representing 70% of the approximately 1,000 patients treated by intensity modulated radiation therapy (IMRT) at the hospital each year, and 20% of the approximately 3,500 patients treated by their Radiation Oncology department each year. In addition to its role in advancing radiation oncology and patient care, this master research and collaboration agreement bears particular significance for Accuray as it represents an opportunity for expanded collaboration captured as a result of Siemens' exit from the radiation therapy business. Siemens has a longstanding collaboration arrangement with University of Heidelberg for both radiology and therapeutic radiation oncology research. With Siemens' exit from the linear accelerator business, the University of Heidelberg will continue to collaborate with Siemens on imaging research, while Accuray will now serve as a therapeutic radiation oncology research partner.